This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove news top-news
article thumbnail

Vertex starts gene therapy Casgevy in five patients 

STAT

MAY 7, 2024

Want to stay on top of the science and politics driving biotech today?  Good morning, incredibly exciting news from the STAT newsroom — two of our reporters, Casey Ross and Bob Herman (or as we call them,  Bob Ross ), were  named Pulitzer finalists  in investigative reporting!

Drug Pricing 266
Drug Pricing Drug Development 266
article thumbnail

Dana-Farber expands studies to be retracted to 6, plus 31 to be corrected over mishandled data

STAT

JANUARY 22, 2024

A review of alleged data manipulation in studies involving four top scientists at Dana-Farber Cancer Institute has led to plans to retract six papers and correct 31 manuscripts, the institute confirmed on Monday.

Hospitals 360
Hospitals 360
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The latest updates on cancer research from the weekend

STAT

APRIL 8, 2024

Want to stay on top of the science and politics driving biotech today?  We have news for you from the annual meeting of the American Association for Cancer Research, and also from the annual meeting of the American College of Cardiology.   Sign up  to get our biotech newsletter in your inbox. Hi, it’s Meghana.

252
252
article thumbnail

New data on liquid biopsy for colorectal cancer detection still underwhelms

STAT

APRIL 3, 2024

Want to stay on top of the science and politics driving biotech today?  Today we talk about how biopharma plans to harness AI for clinical trial design, why two experts think Medicare ought to cover the costly GLP-1 drugs, and what news from Roivant means for its business strategy. Read the rest…

Drug Pricing 246
Drug Pricing Drug Development 246
article thumbnail

The GLP-1 panic is alive and well

STAT

FEBRUARY 7, 2024

Want to stay on top of the science and politics driving biotech today?  Damian here with news of a new biotech venture fund, a bold bet against a billion-dollar deal, and the weight of expectations on Eli Lilly.   Sign up  to get our biotech newsletter in your inbox. Good morning, all. Read the rest…

Drug Pricing 260
Drug Pricing Drug Development 260
article thumbnail

The FDA isn’t afraid to yank a disappointing drug

STAT

FEBRUARY 26, 2024

Want to stay on top of the science and politics driving biotech today?  Damian here with a look at some renewed interest in a yesteryear biotech craze, news of an FDA flex, and a dive into the science of vaccinology.   Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Read the rest…

Drug Pricing 241
Drug Pricing Drug Development Vaccines 241
article thumbnail

When did Wall Street sour on Lilly’s Alzheimer’s drug?

STAT

MARCH 12, 2024

Want to stay on top of the science and politics driving biotech today?  Damian here with news that STAT+, our exclusive source for trusted and authoritative coverage of the life sciences, is on sale this week.   Sign up  to get our biotech newsletter in your inbox. Good morning, everyone.

Drug Pricing 222
Drug Pricing Drug Development 222
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 33,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024